Sign up for Table of Contents Alerts.

Email this page

Print this page

Perspectives

Understanding how kinase-targeted therapies work

Sabrina Arena and Alberto Bardelli

Purchase article for $19

Subscribe to this journal for $129/year

Kinases are central nodes in the cellular pathways that control differentiation, proliferation, apoptosis, motility, and invasion. Most if not all human tumors are thought to bear alterations in one or multiple kinase genes which therefore represent attractive therapeutic targets. Accordingly, intense drug discovery programs have led to the development of clinically effective kinase inhibitors. The road to generate a kinase inhibitor requires, in the initial phase, validation of the oncogenic potential of the corresponding kinase gene in cancer cells. As the catalytic domains of kinases are highly homologous, most inhibitors are predicted to affect multiple kinases. It is therefore important to ensure that a drug of interest acts by direct inhibition of its putative target. To address these issues, we devised a strategy to genetically inactivate the catalytic activity of a given kinase in human cells. This approach generates isogenic cells in which a certain kinase gene is expressed but is devoid of enzymatic activity thus mimicking the chronic pharmacological treatment of cancer cells with a specific and selective kinase inhibitor. This strategy is not limited to kinase genes but could be broadly applicable to any drug/protein combination in which the target enzymatic domain of a gene is known.

Authors

Sabrina Arena

University of Torino Medical School, Candiolo; Milan, Italy

Alberto Bardelli

University of Torino Medical School, Candiolo; Milan, Italy

Purchase article for $19

Subscribe to this journal for $129/year